Intra-Cellular Therapies, Inc. reiterated earnings guidance for the full year 2024. Full year 2024, the company reiterated CAPLYTA net product sales guidance of $645 to $675 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.64 USD | -1.25% | -1.10% | -8.35% |
May. 16 | Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM | |
May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.35% | 6.93B | |
-2.29% | 89.38B | |
-3.68% | 37.92B | |
-14.91% | 32.04B | |
+61.60% | 26.03B | |
-22.72% | 14.14B | |
-8.73% | 12.88B | |
-10.57% | 11.77B | |
+3.67% | 8.92B | |
-17.66% | 7.34B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024